
CureVac N.V. CVAC
Quarterly report 2022-Q2
added 08-18-2022
CureVac N.V. General and Administrative Expenses 2011-2026 | CVAC
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 100 M | - | 42.2 M | 20.4 M | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | 20.4 M | 54.3 M |
Quarterly General and Administrative Expenses CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 24.6 M | - | - | - | 21.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.6 M | 21.3 M | 22.9 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
2.31 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Coherus BioSciences
CHRS
|
101 M | $ 1.63 | -4.4 % | $ 191 M | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.9 B | - | - | $ 96.9 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
186 K | $ 0.73 | -0.03 % | $ 33.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 7.83 | -5.21 % | $ 214 M | ||
|
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
166 M | $ 3.12 | - | $ 649 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | ||
|
Exelixis
EXEL
|
519 M | $ 51.1 | -0.37 % | $ 13.9 B | ||
|
Forte Biosciences
FBRX
|
12.4 M | $ 23.96 | -2.84 % | $ 310 M | ||
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | ||
|
Karyopharm Therapeutics
KPTI
|
105 M | $ 8.9 | 0.56 % | $ 1.08 M | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 4.4 | -7.76 % | $ 1.31 B | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 17.3 | -5.57 % | $ 809 M | ||
|
BioNTech SE
BNTX
|
514 M | $ 91.99 | -0.26 % | $ 22.2 B | ||
|
Compugen Ltd.
CGEN
|
10.9 M | $ 3.03 | 6.32 % | $ 283 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | ||
|
Gilead Sciences
GILD
|
5.77 B | $ 132.06 | -0.74 % | $ 164 B | ||
|
Genmab A/S
GMAB
|
661 M | $ 26.9 | 1.32 % | $ 1.74 B | ||
|
Genprex
GNPX
|
6.09 M | $ 0.86 | 1.2 % | $ 802 K | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.49 | -4.12 % | $ 5.75 M | ||
|
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | ||
|
Grifols, S.A.
GRFS
|
1.26 B | $ 7.79 | 1.04 % | $ 5.29 B | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Fortress Biotech
FBIO
|
96.4 M | $ 2.3 | 3.14 % | $ 64.2 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 21.57 | -0.55 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
28.3 M | $ 9.24 | 36.48 % | $ 264 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K |